- Research article
- Open Access
- Open Peer Review
SMARCB1/INI1 germline mutations contribute to 10% of sporadic schwannomatosis
© Rousseau et al; licensee BioMed Central Ltd. 2011
- Received: 7 October 2010
- Accepted: 24 January 2011
- Published: 24 January 2011
Schwannomatosis is a disease characterized by multiple non-vestibular schwannomas. Although biallelic NF2 mutations are found in schwannomas, no germ line event is detected in schwannomatosis patients. In contrast, germline mutations of the SMARCB1 (INI1) tumor suppressor gene were described in familial and sporadic schwannomatosis patients.
To delineate the SMARCB1 gene contribution, the nine coding exons were sequenced in a series of 56 patients affected with a variable number of non-vestibular schwannomas.
Nine variants scattered along the sequence of SMARCB1 were identified. Five of them were classified as deleterious. All five patients carrying a SMARCB1 mutation had more multiple schwannomas, corresponding to 10.2% of patients with schwannomatosis. They were also diagnosed before 35 years of age.
These results suggest that patients with schwannomas have a significant probability of carrying a SMARCB1 mutation. Combined with data available from other studies, they confirm the clinical indications for genetic screening of the SMARCB1 gene.
- Vestibular Schwannomas
- Somatic Mosaicism
- Germline Alteration
- SMARCB1 Mutation
- Multiple Schwannomas
Neurofibromatoses (NF) are an heterogeneous group of genetic disorders predisposing to various tumors of the nervous system, divided into two well recognized distinct clinical entities, NF1 and NF2. Patients with multiple non-vestibular schwannomas have been assembled into a particular category within neurofibromatoses called schwannomatosis . The SMARCB1 gene has been found to harbor germline alterations in both familial and sporadic schwannomatosis patients [2, 3], with a greater number of spinal schwannomas in familial cases and the presence of meningiomas  although this latter point remains debated . To improve the clinical indications for SMARCB1 molecular screening in medical genetics practice, we evaluated its implication in a series of patients exhibiting non-vestibular schwannomas and no NF2 germline alteration.
Primers used for the analysis of the 9 SMARCB1 coding exons
Point variations and phenotypic description of the patients exhibiting a SMARCB1 variation
11 non-vestibular schwannomas
c.34C > T
Multiple spinal schwannomas
c.[500+5G > T,505G > T]
1 facial nerve
7 spinal schwannomas
c.501-23T > G
2 spinal schwannomas
c.832C > T
Multiple schwannomas and meningiomas
Unilateral V-, VII-, spinal schwannomas
c.[897G > A;986+57_986+58dup;1119-41G > A]
Five mutations were identified through the analysis of the SMARCB1 gene for point mutations in a series of 56 NF2-negative patients affected with non-vestibular schwannomas. Patients carrying a mutation presented with multiple schwannomas at a young age, i.e. 10.2% in schwannomatosis patients  and 20% of patients diagnosed before 35 years of age, none with any family history of schwannomas. This proportion remains lower than that described in familial schwannomatosis [3, 7, 8]; however neither somatic mosaicisms nor genomic rearrangements were investigated [2, 7]. Tumor samples were not available thus precluding dosage analyses and the demonstration of SMARCB1 and/or NF2 somatic inactivation .
Review of the clinical description of SMARCB1 mutation patients affected with non-rhabdoid tumors
1 familial schwannomatosis
case report, initial description
28 sporadic + 15 familial non-vestibular schwannomatosis patients
2/28 + 5/15 mutations
1 familial schwannomatosis with multiple meningiomas
47 NF2-negative patients with multiple meningiomas
21 sporadic schwannomatosis patients
1 familial meningiomatosis
This work was supported by the French national cancer institute INCa through a grant dedicated to the PHRATries network (Prédispositions Héréditaires Rares Aux Tumeurs, Réseau d'Identification Et de Soins). We are grateful to the French clinicians who faithfully entrust our institution with molecular genetics tests of neurofibromatoses.
- Lu-Emerson C, Plotkin SR: The neurofibromatoses. Part 2: NF2 and schwannomatosis. Rev Neurol Dis. 2009, 6: E81-86.PubMedGoogle Scholar
- Hulsebos TJ, Plomp AS, Wolterman RA, Robanus-Maandag EC, Baas F, Wesseling P: Germline mutation of INI1/SMARCB1 in familial Schwannomatosis. Am J Hum Genet. 2007, 80: 805-810. 10.1086/513207.View ArticlePubMedPubMed CentralGoogle Scholar
- Hadfield KD, Newman WG, Bowers NL, Wallace A, Bolger C, Colley A, McCann E, Trump D, Prescott T, Evans DG: Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. J Med Genet. 2008, 45: 332-339. 10.1136/jmg.2007.056499.View ArticlePubMedGoogle Scholar
- Bacci C, Sestini R, Provenzano A, Paganini I, Mancini I, Porfirio B, Vivarelli R, Genuardi M, Papi L: Schwannomatosis associated with multiple meningiomas due to a familial SMARCB1 mutation. Neurogenetics. 2010, 11: 73-80. 10.1007/s10048-009-0204-2.View ArticlePubMedGoogle Scholar
- Hadfield KD, Smith MJ, Trump D, Newman WG, Evans DG: SMARCB1 mutations are not a common cause of multiple meningiomas. J Med Genet. 2010, 47: 567-568. 10.1136/jmg.2009.075721.View ArticlePubMedGoogle Scholar
- MacCollin M, Chiocca EA, Evans DG, Friedman JM, Horvitz R, Jaramillo D, Lev M, Mautner VF, Niimura M, Plotkin SR, Sang CN, Stemmer-Rachamimov A, Roach ES: Diagnostic criteria for schwannomatosis. Neurology. 2005, 64: 1838-1845. 10.1212/01.WNL.0000163982.78900.AD.View ArticlePubMedGoogle Scholar
- Boyd C, Smith MJ, Kluwe L, Balogh A, Maccollin M, Plotkin SR: Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis. Clin Genet. 2008, 74: 358-366. 10.1111/j.1399-0004.2008.01060.x.View ArticlePubMedGoogle Scholar
- Hulsebos TJ, Kenter SB, Jakobs ME, Baas F, Chong B, Delatycki MB: SMARCB1/INI1 maternal germline mosaicism in schwannomatosis. Clin Genet. 2010, 77: 86-91. 10.1111/j.1399-0004.2009.01249.x.View ArticlePubMedGoogle Scholar
- Sestini R, Bacci C, Provenzano A, Genuardi M, Papi L: Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas. Hum Mutat. 2008, 29: 227-231. 10.1002/humu.20679.View ArticlePubMedGoogle Scholar
- Christiaans I, Kenter SB, Brink HC, van Os TA, Baas F, van den Munckhof P, Kidd AM, Hulsebos TJ: Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas. J Med Genet. 2010Google Scholar
- Smith MJ, Boyd CD, MacCollin MM, Plotkin SR: Identity analysis of schwannomatosis kindreds with recurrent constitutional SMARCB1 (INI1) alterations. Clin Genet. 2009, 75: 501-502. 10.1111/j.1399-0004.2009.01184.x.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2377/11/9/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.